Live Q&A: Ulcerative Colitis in the 21st Century: Incorporating Guidelines and Real-World Evidence in Practice to Enhance Patient-Centered Care
Premiere Date: Thursday, October 8, 2020This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, October 8, 2021
Note: Credit Is No Longer Available
 | David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Director, Inflammatory Bowel Disease Center University of Chicago Medicine Chicago, IL |
 | Miguel Regueiro, MD, AGAF, FACG, FACP Chair, Digestive Disease and Surgery Chair, Department of Gastroenterology, Hepatology, and Nutrition The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology Professor, Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, OH |
Ulcerative colitis (UC) is a heterogeneous disorder that requires an individualized approach in order to achieve goals of treatment such as mucosal healing and deep, long-term remission. The American College of Gastroenterology (ACG) released updated treatment guidelines in 2019 that include recommendations for disease stratification, prognosis, treatment options, and disease monitoring. These guidelines, along with new efficacy, safety, and comparative effectiveness data and the approval of additional therapies, facilitate the identification of the right treatment for the right patient at the right time. Clinicians who care for patients with UC must ensure that they are aware of these updates and incorporate them into practice in order to optimize patient outcomes.
This live question and answer session is your opportunity to ask questions of our expert faculty. The original virtual symposium featured the UC guideline authors discussing the newest recommendations and their translation to practice. To view the full activity ahead of this live Q&A, click here.
At the end of this CE activity, participants should be able to:
- Follow the updated UC guidelines to incorporate elements of prognosis into diagnosis and treatment decision-making.
- Incorporate data on efficacy, safety, comparative effectiveness, and different routes of administration from clinical trials and real-world experience into treatment decision-making in moderate-to-severe UC.
- Implement strategies for improving patient-centered care and SDM in moderate-to-severe UC.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify the updated UC guidelines for diagnosis and treatment decision-making for patients with UC.
- Summarize data on efficacy, safety, comparative effectiveness, and different routes of administration from clinical trials and real-world experience for treatment decision-making in moderate-to-severe UC.
- Describe strategies for improving patient-centered care and SDM in moderate-to-severe UC.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, PAs, nurse practitioners, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-20-122-L01-P
Type: knowledge-based
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.
Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Bristol-Myers Squibb Company; Dizal Pharmaceutical; Eli Lilly and Company; Ferring Pharmaceuticals Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He receives other financial or material support as a member of the Board of Trustees for the American College of Gastroenterology; and as Co-Founder, CFO of Cornerstones Health, Inc. (non-profit).
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on advisory boards and a consultant for AbbVie Inc.; Allergan; Amgen Inc.; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMQ-097-100820-20
